- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07599696
Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements
14. mai 2026 oppdatert av: Thea Knowles, Michigan State University
Speech Amplification Devices for Parkinson and Related Diseases: Talker- and Technology-Driven Enhancements
The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease.
By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia.
The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.
Studieoversikt
Status
Rekruttering
Intervensjon / Behandling
Detaljert beskrivelse
Though intensive behavioral speech intervention is considered the "gold standard" for treating hypophonia in Parkinson's disease (PD), many individuals struggle to transfer or maintain these behavioral strategies into their daily communication.
This is because PD, affecting over six million people worldwide, is a progressive, neurodegenerative disorder that also impairs cognition, sensorimotor integration, and fatigue.
Speech amplification devices are a type of augmentative technology that have been shown to improve communication related outcomes in PD.
Amplification devices increase the volume of a person's natural speech and can be used on their own or to augment behavioral speech outcomes.
The specific acoustic mechanisms underlying these benefits are unknown, though previous evidence suggests that increased signal intensity alone is not responsible for improved auditory-perceptual outcomes.
The overall goal of this proposal is to identify the relationship between acoustic and perceptual consequences of amplification devices with and without the use of behavioral speech strategies.
Aim 1 of this proposal will quantify the acoustic and auditory-perceptual effects of speech amplification devices for talkers with PD.
In addition to using an amplification device, participants will speak with both their habitual speech style and a hyperarticulated, clear speech style.
Aim 2 will identify the contribution of resultant acoustic features as well as targeted acoustic enhancements that optimize intelligibility in amplified speech.
Acoustic modifications that impact the relative contributions of low to high frequency spectral energy will be made to a subset of the speech recordings from Aim 1.
These acoustic enhancements will serve to simulate potential technological improvements to amplification devices.
Naïve listeners will hear the speech recordings made in Aims 1 and 2 and will provide measures of listener accuracy and effort.
Improvements in speech intelligibility of amplified speech are hypothesized to be associated with acoustic measures that reflect relative greater high to low frequency components of the speech signal.
The most positive change is hypothesized to occur when talkers combine behavioral speech strategies with amplification compared to behavioral changes or amplified speech alone.
Furthermore, auditory-perceptual outcomes are hypothesized to improve following implementation signal enhancements that could be directly integrated into future amplification device development.
Collectively, this study will identify ways to maximize speech treatment outcomes of speech amplification devices through behavioral changes made by the talker or acoustic enhancements to the device output itself.
Results will guide behavioral treatment strategies and future device modifications that will improve the efficacy of speech amplifiers in this population.
This work is innovative for establishing ways to leverage behavioral speech strategies with advances in augmentative technology for PD.
It is theoretically significant for defining the role of spectral acoustics in auditory-perceptual outcomes in disordered speech.
It is clinically significant for advancing patient-centered augmentative speech treatment technology for PD.
Studietype
Intervensjonell
Registrering (Antatt)
100
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Thea Knowles, PhD
- Telefonnummer: 517-353-6401
- E-post: thea@msu.edu
Studiesteder
-
-
Michigan
-
East Lansing, Michigan, Forente stater, 48823
- Rekruttering
- Michigan State University
-
Ta kontakt med:
- Thea Knowles, PhD
- Telefonnummer: 517-353-6401
- E-post: thea@msu.edu
-
Hovedetterforsker:
- Thea Knowles, PhD
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Dominant speakers of North American English
- Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP/MSA/PSP)
- Present with changes in their speech/voice
Exclusion Criteria:
- History of any other speech, language, or neurological concern other than Parkinson/parkinsonism.
- Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and/or use of a cochlear implant.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Speech Study
Single arm study: All speech conditions are administered.
|
Behavioral speech strategies + speech amplification
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Speech intensity
Tidsramme: Day 1
|
Decibel sound pressure level (dB SPL) measured from speech audio recordings
|
Day 1
|
|
Voice quality
Tidsramme: Day 1
|
Cepstral peak prominence smoothed (CPPS), measured in decibels (dB) from speech audio recordings
|
Day 1
|
|
Articulation
Tidsramme: Day 1
|
Quadrilateral vowel articulation index, measured as a composite of first and second formants in Herz (Hz) across four vowels in speech audio recordings.
|
Day 1
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Speech intelligibility
Tidsramme: From end of speech study enrollment to within 1 year. Perceptual measures are elicited from naive listeners following the speech recording study.
|
% words correctly understood by naive listeners (0% = no words correctly transcribed; 100% = all words correctly transcribed).
Listener participants transcribe speech recorded by speaker participants.
|
From end of speech study enrollment to within 1 year. Perceptual measures are elicited from naive listeners following the speech recording study.
|
|
Perceived Listener Effort
Tidsramme: From end of speech study enrollment to within 1 year. Listener effort will be elicited from naive listeners following the speech recording study.
|
% along a visual analogue scale (0 = "no effort required to understand the speech"; 100 = "maximal effort required to understand the speech").
Listener participants will rate speech recorded by speaker participants.
|
From end of speech study enrollment to within 1 year. Listener effort will be elicited from naive listeners following the speech recording study.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. mars 2024
Primær fullføring (Antatt)
31. desember 2027
Studiet fullført (Antatt)
31. mai 2028
Datoer for studieregistrering
Først innsendt
5. mai 2026
Først innsendt som oppfylte QC-kriteriene
14. mai 2026
Først lagt ut (Faktiske)
20. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
20. mai 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
14. mai 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Synukleinopatier
- Nevrologiske manifestasjoner
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Sykdommer i luftveiene
- Nevroatferdsmanifestasjoner
- Nevrodegenerative sykdommer
- Otorhinolaryngologiske sykdommer
- Bevegelsesforstyrrelser
- Parkinsonlidelser
- Basal ganglia sykdommer
- Laryngeale sykdommer
- Kommunikasjonsforstyrrelser
- Språkforstyrrelser
- Artikulasjonsforstyrrelser
- Patologiske tilstander, tegn og symptomer
- Oppførsel
- Tegn og symptomer
- Kommunikasjon
- Muntlig oppførsel
- Parkinsons sykdom
- Taleforstyrrelser
- Stemmeforstyrrelser
- Dysartri
- Tale
Andre studie-ID-numre
- 00008898
- R21DC021798 (U.S. NIH-stipend/kontrakt)
- CurePSP CARES Grant - Knowles (Annet stipend/finansieringsnummer: CurePSP)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .